Abstract
BackgroundPrimary ovarian signet-ring cell carcinoma is extremely rare, with only five recent case reports. Almost all reported cases of ovarian signet-ring cell carcinoma have been treated with TC therapy and none have reported regarding the use of S-1/CDDP therapy. We report a case of primary ovarian signet-ring cell carcinoma treated postoperatively with S-1/CDDP therapy.Case presentationWe describe a 55-year-old woman diagnosed with stage IB primary ovarian signet-ring cell carcinoma that was treated with S-1/CDDP therapy. Preoperative transvaginal ultrasonography and contrast-enhanced computed tomography (CT) revealed a solid tumor measuring 10 cm in diameter in the pelvis. The tumor marker levels were as follows: CA125, 41.6 U/mL; CA19–9, < 2.0 U/mL; and CEA, 2.2 ng/mL. Ovarian cancer was suspected, and total abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy were performed. The left ovary was enlarged to greater than fist-sized, and there was a small amount of clear yellow ascites. Histological examination of the left ovary led to the diagnosis of signet-ring cell carcinoma. Histological examination of the right ovary also showed the presence of a signet-ring cell carcinoma. After surgery, upper and lower gastrointestinal endoscopy and positron-emission tomography-CT were performed to search for a possible primary lesion, but none was found. The patient was diagnosed with primary ovarian signet-ring cell carcinoma with FIGO Stage IB (PT1b, NX, M0). As postoperative adjuvant chemotherapy, S-1/CDDP therapy (S-1120 mg/day/body × 14 days, CDDP 50 mg/m2 day 8, q 21 days) was administered for six cycles. There was no recurrence 27 months after the initial treatment.ConclusionsWe considered S-1/CDDP therapy was effective for primary ovarian signet-ring cell carcinoma. This is the first case report of primary ovarian signet-ring cell carcinoma treated with S-1/CDDP therapy in the world.
Highlights
Primary ovarian signet-ring cell carcinoma is extremely rare, with only five recent case reports
We considered S-1/CDDP therapy was effective for primary ovarian signet-ring cell carcinoma
Almost all reported cases of ovarian signet-ring cell carcinoma have been treated with TC therapy and none have reported regarding the use of S-1/CDDP therapy
Summary
Ovarian signet-ring cell carcinomas are mostly metastasis of cancers of digestive organs such as stomach and large bowel (so-called Krukenberg tumors) and account for approximately 2% of all ovarian cancers [1]. We report a case of primary ovarian signet-ring cell carcinoma treated postoperatively with S-1/CDDP therapy along with a literature review. Shoji et al Journal of Ovarian Research (2020) 13:33 years and underwent menopause at 51 years of age She was referred to our institution with a chief complaint of irregular vaginal bleeding; cytological examination of the uterine cervix and endometrium showed no abnormalities. The left ovary was solid and enlarged to 6 × 6 cm, but because there were no subjective symptoms and her CA125 level was 23 U/mL, the patient was followed up. Magnetic resonance imaging was not performed because the patient had claustrophobia She was diagnosed as having a solid ovarian tumor and underwent laparotomy. No recurrence was found 27 months after the initial surgery
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
